<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113761</url>
  </required_header>
  <id_info>
    <org_study_id>BE77201318160</org_study_id>
    <nct_id>NCT02113761</nct_id>
  </id_info>
  <brief_title>Non Invasive Mapping Before Ablation for Atrial Fibrillation.</brief_title>
  <acronym>AFACART</acronym>
  <official_title>Non Invasive Mapping Before Ablation for Atrial Fibrillation: the Afacart Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Brugmann</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE / CONTEXT The ECG records the electrical activity propagating along cardiac cells&#xD;
      (from the atria to the ventricles). The standard 12 ECG leads placed on the chest measure the&#xD;
      global activation of the heart and do not have the ability to detect small-scale disturbances&#xD;
      or to pinpoint ectopic activity. By the 1960s, multiple electrodes were placed around the&#xD;
      chest to try to understand the complexity of the distribution of electrical activity in&#xD;
      relation to the single cardiothoracic geometry of each individual. The safety of this method&#xD;
      is similar to the ECG but its superiority has been demonstrated by the detection of anomalies&#xD;
      imperceptible to the standard ECG. The accuracy of the technique in localizing rhythm&#xD;
      disturbances is on the order of 5 mm.&#xD;
&#xD;
      OBJECTIVES Main objective: To evaluate the utility of noninvasive mapping during persistent&#xD;
      AF electrophysiology procedure&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. Compare the effectiveness of noninvasive mapping compared to conventional standard of&#xD;
           care methods for AF mapping and ablation procedure.&#xD;
&#xD;
        2. Evaluate the absence of recurrence of persistent AF after a follow up of 12 months after&#xD;
           the procedure during a scheduled hospitalization.&#xD;
&#xD;
      DIAGRAM OF RESEARCH European Diagnostic Study, feasibility, non-randomized, multi center&#xD;
&#xD;
      RESEARCH PROCEDURES A trained clinical specialist places 252 dry gelled ECG electrodes on the&#xD;
      patient's torso. The 252 ECG electrode array is hooked up to the CardioInsight system and&#xD;
      body surface ECG recordings are made during the patient's arrhythmia. The patient is then&#xD;
      sent to the radiology department for a CT scan (no contrast) to image both the heart and&#xD;
      electrodes on the patient's torso. A trained clinical specialist from CardioInsight then&#xD;
      segments the CT DICOM images from the CT scan to obtain epicardial anatomy and establish&#xD;
      heart-torso geometry.&#xD;
&#xD;
      The electrograms are processed by the system to produce movies of fibrillatory activity (both&#xD;
      focal activity, and rotor activity).&#xD;
&#xD;
      PROCEDURAL ENDPOINTS Primary endpoint: Acute AF termination to atrial tachycardia or sinus&#xD;
      rhythm&#xD;
&#xD;
      Secondary outcome criteria:&#xD;
&#xD;
        -  Reduction in RF time compared to standard of care (historical control - comparable&#xD;
           patient population)&#xD;
&#xD;
        -  Reduction in procedure time compared to standard of care (historical control -&#xD;
           comparable patient population)&#xD;
&#xD;
        -  Freedom from persistent AF at the end of the 12 months F/U period STUDY SIZE&#xD;
&#xD;
      The sample size was estimated at 100 patients, with up to 20 patients per center STUDY&#xD;
      CENTERS 8 Centers :&#xD;
&#xD;
        -  Brugmann - Brussels (Belgium)&#xD;
&#xD;
        -  Clinique Pasteur - Toulouse (France)&#xD;
&#xD;
        -  Medizinische Klinik und Poliklinik - Mainz (Germany)&#xD;
&#xD;
        -  University ed Herzzentrum Freiburg Bad Kozingen (Germany)&#xD;
&#xD;
        -  Deutsches Herzzentrum München, Munich (Germany)&#xD;
&#xD;
        -  Kerkhoff Klinik, Bad Nauheim, (Germany)&#xD;
&#xD;
        -  Sint-Jan Sint-Franciscus Xaverius, Brugge (Belgium)&#xD;
&#xD;
        -  Clinique Ambroise Paré, Paris, France&#xD;
&#xD;
      EXPECTED OUTCOME In patients referred for ablation of persistent AF, ECG mapping data will be&#xD;
      correlated to the invasive procedure. It is expected that procedure time will be&#xD;
      statistically shorter and total RF energy delivery is expected to be smaller than that of&#xD;
      standard of care for AF treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 21, 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>radiofrequency duration</measure>
    <time_frame>1 day (At the end of the procedure)</time_frame>
    <description>Radiofrequency duration necessary to terminate atrial fibrillation and total radiofrequency duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial fibrillation termination</measure>
    <time_frame>At the time of the procedure of catheter ablation</time_frame>
    <description>Amount of patients with AF termination into sinus rhythm or atrial tachycardia during AF ablation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation recurrence</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with persistent atrial fibrillation as described by the Consensus Statement and&#xD;
        with an indication for atrial fibrillation catheter ablation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female Adults (≥18 years old)&#xD;
&#xD;
          -  Minors (15-18 years) of both sexes subject to parental consent or legal representative&#xD;
&#xD;
          -  Persistent AF ablation refractory to drugs&#xD;
&#xD;
          -  Persistent AF (as defined by consensus statement) for ≤ 12 month duration&#xD;
&#xD;
          -  Consent signed by the patient after reading the information leaflet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous left atrial (LA) ablation&#xD;
&#xD;
          -  Any previous LA or RA surgery&#xD;
&#xD;
          -  Current intra-cardiac thrombus&#xD;
&#xD;
          -  Presence of any pulmonary vein stents&#xD;
&#xD;
          -  Presence of any pre-existing pulmonary vein stenosis&#xD;
&#xD;
          -  Anteroposterior LA diameter &gt; 5.5 cm by TTE or CT&#xD;
&#xD;
          -  Presence of any cardiac valve prosthesis&#xD;
&#xD;
          -  Clinically significant mitral valve regurgitation or stenosis&#xD;
&#xD;
          -  Myocardial infarction, PCI / PTCA or coronary artery stenting within the last 3 months&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Any cardiac surgery within the last 3 months&#xD;
&#xD;
          -  NYHA class III or IV congestive heart failure&#xD;
&#xD;
          -  Uncontrolled hyperthyroidism&#xD;
&#xD;
          -  Any cerebral ischemic event (strokes or TIAs) which occurred during the 6 months&#xD;
             interval preceding the consent Date.&#xD;
&#xD;
          -  Life expectancy less than one (1) year&#xD;
&#xD;
          -  Current or anticipated participation in any other clinical trial of a drug, device or&#xD;
             biologic should be done only after prior consultation and approval of the&#xD;
             investigator(s)&#xD;
&#xD;
          -  Unwilling or unable to comply fully with study procedures and follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Pr Sébastien Knecht</investigator_full_name>
    <investigator_title>PMD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

